{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:29:14Z","timestamp":1715567354169},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2016]]},"DOI":"10.2169\/internalmedicine.55.7518","type":"journal-article","created":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T22:15:42Z","timestamp":1480544142000},"page":"3435-3440","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate\/Emtricitabine to Abacavir Sulfate\/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients"],"prefix":"10.2169","volume":"55","author":[{"given":"Hirotaka","family":"Arae","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ryukyu University Hospital, Japan"},{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Tateyama","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideta","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tasato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Kami","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Miyagi","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ryukyu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ryukyu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Uehara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ryukyu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Moromi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ryukyu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ryukyu University Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics, Control and Prevention of Infectious Diseases, Graduate School of Medicine, University of the Ryukyus, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. May MT, Sterne JA, Costagliola D, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analyses. Lancet 368: 451-458, 2006.","DOI":"10.1016\/S0140-6736(06)69152-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 6: e22698, 2011.","DOI":"10.1371\/journal.pone.0022698"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells\/mm<sup>3<\/sup> on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 46: 72-77, 2007.","DOI":"10.1097\/QAI.0b013e318134257a"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 92: 2506-2512, 2007.","DOI":"10.1210\/jc.2006-2190"},{"key":"5","unstructured":"5. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2015 at: http:\/\/AIDSinfo.nih.gov"},{"key":"6","unstructured":"6. European AIDS Clinical Society (EACS). Guidelines for treatment of HIV-infected adults in Europe, version 8.0, 2015 at: http:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/eacs-guidelines.html"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sax PE, Tierney C, Collier AC, et al. Abacavir\/lamivudine versus tenofovir DF\/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204: 1191-1201, 2011.","DOI":"10.1093\/infdis\/jir505"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin infect Dis 51: 496-505, 2010.","DOI":"10.1086\/655681"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses 25: 387-394, 2009.","DOI":"10.1089\/aid.2008.0202"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One 6: e22661, 2011.","DOI":"10.1371\/journal.pone.0022661"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51: 963-972, 2010.","DOI":"10.1086\/656417"},{"key":"12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","volume":"26","author":"R Bedimo","year":"2010","unstructured":"12. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 26: 825-831, 2010.","journal-title":"AIDS","ISSN":"http:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5: 203-211, 2004.","DOI":"10.1517\/phgs.5.2.203.27481"},{"key":"14","unstructured":"14. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 139-144, 1996."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 15: 227-233, 2010.","DOI":"10.3851\/IMP1518"},{"key":"16","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","volume":"24","author":"M Tungsiripat","year":"2010","unstructured":"16. Tungsiripat M, Kitch D, Glesby MJ, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG5206. AIDS 24: 1781-1784, 2010.","journal-title":"AIDS","ISSN":"http:\/\/id.crossref.org\/issn\/0269-9370","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fabbiani M, Bracciale L, Doino M, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 66: 682-683, 2011.","DOI":"10.1093\/jac\/dkq464"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir\/ritonavir+lamivudine in HIV-infected patients onstable treatment with two nucleos(t)ide reverse transcriptase inhibitors+atazanavir\/ritonavir with virologicalsuppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 68: 1364-1372, 2013.","DOI":"10.1093\/jac\/dkt007"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kurita T, Kitaichi T, Nagao T, Miura T, Kitazono Y. Safety analysis of Epzicom<sup>\u00ae<\/sup> (lamivudine\/abacavir sulfate) in post-marketing surveillance in Japan. Pharmacoepidemiol Drug Saf 23: 372-381, 2014.","DOI":"10.1002\/pds.3588"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sakamoto T, Kojima S, Ogawa H, et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. Am J Cardiol 97: 1165-1171, 2006.","DOI":"10.1016\/j.amjcard.2005.11.031"},{"key":"21","unstructured":"21. Mabuchi H, Kita T, Matsuzaki M, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simbastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66: 1096-1100, 2002."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Mabuchi H, Kita T, Matsuzaki M, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simbastatin therapy in Japanese patients with hypercholesterolemia: primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 66: 1087-1095, 2002.","DOI":"10.1253\/circj.66.1096"},{"key":"23","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1161\/01.CIR.89.6.2533","volume":"89","author":"A Kitamura","year":"1994","unstructured":"23. Kitamura A, Iso H, Naito Y, et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 89: 2533-2539, 1994.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Satoh H, Nishino T, Tomita K, et al. Risk factors and the incidence of coronary artery disease in young middle-aged Japanese men: results from a 10-year cohort study. Intern Med 45: 235-239, 2006.","DOI":"10.2169\/internalmedicine.45.1532"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Maruyama K, Hirobe K, Noda H, et al. Associations between blood lipid profiles and risk of myocardial infarction among Japanese male workers: 3M study. J Atheroscler Thromb 16: 714-721, 2009.","DOI":"10.5551\/jat.547"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Noda H, Iso H, Saito I, et al. The impact of the metabolic syndrome and its components on the incidence of ischemic heart disease and stroke: the Japan public health center-based study. Hypertens Res 32: 289-290, 2009.","DOI":"10.1038\/hr.2009.14"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/23\/55_55.7518\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:57:23Z","timestamp":1568606243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/55\/23\/55_55.7518\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":26,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.55.7518","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}